Sanofi Partners with AlphaDetect to Enhance Detection of Alpha-1 Antitrypsin Deficiency
Sanofi has announced its support for AlphaDetect, a nonprofit organization focused on accelerating the detection of Alpha-1 Antitrypsin Deficiency (Alpha-1). This partnership aims to enhance the routine detection of this genetic condition, which is often underdiagnosed and can lead to severe lung and liver diseases. AlphaDetect, powered by the Alpha-1 Foundation, is working to increase awareness and adoption of testing recommendations in clinical practice. Sanofi's involvement as an inaugural industry sponsor will help expand detection strategies and support healthcare providers in identifying at-risk individuals. The initiative is crucial as more than 90% of those affected by Alpha-1 remain unidentified, despite it being a significant genetic risk factor for conditions like COPD. 
